Bashar A. Aqel, Surakit Pungpapong, Michael Leise, K. Tuesday Werner, Amy E. Chervenak, Kymberly D. Watt, Jennifer L. Murphy, Kristen Ryland, Andrew P. Keaveny, Ryan McLemore, Hugo E. Vargas – 11 June 2015 – Interferon (IFN)‐free regimens are needed to treat hepatitis C virus (HCV) infection. Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along with minimal adverse events (AEs) in patients with hepatitis C genotype 1 (HCV GT1).

Erik Lontok, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand, Oliver Lenz, Fiona McPhee, Hongmei Mo, Neil Parkin, Tami Pilot‐Matias, Veronica Miller – 10 June 2015 – Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon‐free, all‐oral combinations of direct‐acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions.

Eloi R. Verrier, Stefan Wieland, Thomas F. Baumert – 10 June 2015

Erik Lontok, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand, Oliver Lenz, Fiona McPhee, Hongmei Mo, Neil Parkin, Tami Pilot‐Matias, Veronica Miller – 10 June 2015 – Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon‐free, all‐oral combinations of direct‐acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions.

Xu Yang, Xiao‐peng Tang, Yong‐hong Zhang, Kai‐zhong Luo, Yong‐fang Jiang, Hong‐yu Luo, Jian‐hua Lei, Wen‐long Wang, Ming‐ming Li, Han‐chun Chen, Shi‐lin Deng, Li‐ying Lai, Jun Liang, Min Zhang, Yi Tian, Yun Xu – 10 June 2015 – Hepatic copper determination is an important test for the diagnosis of Wilson's disease (WD). However, the method has not been standardized, the diagnostic accuracy has not been evaluated prospectively, and the optimal cut‐off value remains controversial.

Kiran M. Bambha, Jennifer L. Dodge, Jane Gralla, David Sprague, Scott W. Biggins – 10 June 2015 – With increasing attention being paid to optimizing patient outcomes, it has been proposed that liver transplantation (LT) for individuals with elevated body mass index (BMI) values and high Model for End‐Stage Liver Disease (MELD) scores may adversely affect post‐LT outcomes. We investigated the impact of BMI on post‐LT outcomes in the context of MELD at LT.

Carolina Jiménez Calvente, Alfica Sehgal, Yury Popov, Yong Ook Kim, Victor Zevallos, Ugur Sahin, Mustafa Diken, Detlef Schuppan – 10 June 2015 – Fibrosis accompanies the wound‐healing response to chronic liver injury and is characterized by excessive hepatic collagen accumulation dominated by collagen type I. Fibrosis often progresses to cirrhosis.

Torsten Voigtländer, Elmar Jaeckel, Frank Lehner, Michael P. Manns, Tim O. Lankisch – 9 June 2015 – Secondary sclerosing cholangitis in critically ill patients (SSC‐CIP) is a destructive cholangiopathy with a poor prognosis. Liver transplantation (LT) is an established therapeutic option in end‐stage liver disease but is insufficiently evaluated in patients with SSC‐CIP. Our aim was the retrospective analysis of the outcome and complications of patients with SSC‐CIP undergoing LT between 2002 and 2012.

Jan Knaak, Nazia Selzner, Markus Selzner – 9 June 2015

Patricia Martinez‐Ortega, Fernando Rotellar, Pablo Marti‐Cruchaga, Gabriel Zozaya, Carlos Sanchez‐Justicia, Fernando Pardo – 9 June 2015